We acquire drug development programs as early as
the start of IND-enabling studies
Boston Pharmaceuticals leverages a highly experienced drug development team to generate clinical data to create value for our organization and our partners. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.
We believe in three fundamental concepts:
- Our industry suffers from a chronic mismatch between the flow of innovation and resource availability at any point in time.
- Access to development expertise and appropriate funding can be the key catalyst for drug development programs to reach their full potential.
- The demonstration of true clinical proof-of-concept is a key value-creation step in the clinical development of a medicine.
In building our portfolio, we are agnostic to therapeutic area, modality, and technology. Our team of scientists and clinicians have expertise across multiple disease areas, mechanisms, and molecule types. We are data-driven and rigorously pursue a thorough understanding of the biology, mechanism, and potential therapeutic differentiation before committing to a program. We apply a disciplined, objective approach to drug development, incorporating interim analyses and milestones to de-risk our investments before major capital commitments are made.
How We Work
Our internal team of experts designs and leads our programs.
Complementing the Boston Pharmaceuticals team is a network of best-in-class development partners strategically integrated into our programs. This blended model allows us to flexibly scale across programs, return more value to our partners and ultimately bring the best medicines to patients.